SURINABANT


Synonyms	SR-147778 Sr147778 Surinabant
Status
Molecule Category	UNKNOWN
UNII	SF8R9VCB0X
EPA CompTox	DTXSID2047357


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	HMXDWDSNPRNUKI-UHFFFAOYSA-N
Smiles	CCc1c(C(=O)NN2CCCCC2)nn(-c2ccc(Cl)cc2Cl)c1-c1ccc(Br)cc1
InChI	InChI=1S/C23H23BrCl2N4O/c1-2-18-21(23(31)28-29-12-4-3-5-13-29)27-30(20-11-10-17(25)14-19(20)26)22(18)15-6-8-16(24)9-7-15/h6-11,14H,2-5,12-13H2,1H3,(H,28,31)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C23H23BrCl2N4O
Molecular Weight	522.27
AlogP	6.3
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	5.0
Polar Surface Area	50.16
Molecular species	NEUTRAL
Aromatic Rings	3.0
Heavy Atoms	31.0

Bioactivity

Mechanism of Action	Action	Reference
Cannabinoid CB1 receptor antagonist	ANTAGONIST	PubMed


Protein: Cannabinoid CB1 receptor Description: Cannabinoid receptor 1 Organism : Homo sapiens P21554 ENSG00000118432

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Membrane receptor Family A G protein-coupled receptor Small molecule receptor (family A GPCR) Lipid-like ligand receptor (family A GPCR) Cannabinoid receptor	-	-	-	4	-

Assay Description	Organism	Bioactivity	Reference
Inhibition of [3H]CP-55940 binding to human cannabinoid receptor 1	Homo sapiens	3.5 nM
Inhibition of [3H]CP-55940 binding to human cannabinoid receptor 2	Homo sapiens	442.0 nM

Related Entries

Cross References

Resources	Reference
ChEBI	125484
ChEMBL	CHEMBL189676
DrugBank	DB13070
FDA SRS	SF8R9VCB0X
Guide to Pharmacology	9233
PubChem	9849616
SureChEMBL	SCHEMBL675894
ZINC	ZINC000001549068

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).